Skip to content
10-Q

Quarterly Report

Enliven Therapeutics, Inc. ELVN

0001193125-26-211982

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 28, 2026 60.9M sh
Shares Diluted Q1 2026 · Mar 31, 2026 62.8M sh
Shares Diluted Q1 2026 · Mar 31, 2025 50.05M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $20K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$19.29M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$24.13M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $132.18M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $98.9M
Stockholders Equity Q1 2026 · Mar 31, 2026 $453.37M
Stockholders Equity Q1 2026 · Dec 31, 2025 $459.6M
Stockholders Equity Q1 2026 · Mar 31, 2025 $288.3M
Stockholders Equity Q1 2026 · Dec 31, 2024 $309.85M
Current Liabilities Q1 2026 · Mar 31, 2026 $11.49M
Current Liabilities Q1 2026 · Dec 31, 2025 $16.57M
Total Liabilities Q1 2026 · Mar 31, 2026 $11.49M
Total Liabilities Q1 2026 · Dec 31, 2025 $16.57M
Current Assets Q1 2026 · Mar 31, 2026 $463.14M
Current Assets Q1 2026 · Dec 31, 2025 $474.88M
Total Assets Q1 2026 · Mar 31, 2026 $464.85M
Total Assets Q1 2026 · Dec 31, 2025 $476.17M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.38
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.57
Eps Basic Q1 2026 · Mar 31, 2026 −$0.38
Eps Basic Q1 2026 · Mar 31, 2025 −$0.57
Sga Expense Q1 2026 · Mar 31, 2026 $7.14M
Sga Expense Q1 2026 · Mar 31, 2025 $6.8M
Rd Expense Q1 2026 · Mar 31, 2026 $20.69M
Rd Expense Q1 2026 · Mar 31, 2025 $24.9M
Net Income Q1 2026 · Mar 31, 2026 −$23.63M
Net Income Q1 2026 · Mar 31, 2025 −$28.54M
Operating Income Q1 2026 · Mar 31, 2026 −$27.82M
Operating Income Q1 2026 · Mar 31, 2025 −$31.69M